Medical Condition

mantle cell lymphoma

Total Trials

10

Recruiting Now

10

Trial Phases

Phase 1, Phase 3, Phase 1, Phase 2

Lymphoma trials span diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin lymphoma, mantle cell lymphoma, and T-cell lymphomas β€” each with distinct biology and treatment response. CAR-T cell therapy has established a new standard in relapsed/refractory DLBCL, and trials now aim to move this approach earlier in the treatment sequence.

Active trials evaluate bispecific antibodies (mosunetuzumab, epcoritamab, glofitamab), next-generation CAR-T cell products (CD19/CD22 dual targets, BCMA-targeting), BTK inhibitors in B-cell lymphomas, and total metabolic volume on PET as a predictive biomarker for treatment adaptation.

Frequently Asked Questions — mantle cell lymphoma Clinical Trials

How many clinical trials are currently recruiting for mantle cell lymphoma?

ClinicalMetric currently tracks 10 actively recruiting clinical trials for mantle cell lymphoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for mantle cell lymphoma?

mantle cell lymphoma research spans Phase 1 (4 trials), Phase 2 (4 trials), Phase 3 (2 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a mantle cell lymphoma clinical trial?

Eligibility criteria for mantle cell lymphoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Phase 3

Top Sponsors

Paolo Caimi, MD 1 trial

BeOne Medicines 1 trial

OncoNano Medicine, Inc. 1 trial

OHSU Knight Cancer Institute 1 trial

University Hospital Heidelberg 1 trial

Recruiting Clinical Trials

NCT07225439 Phase 1

Recruiting

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

Enrollment

300 pts

Location

United States, Argen...

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

Enrollment

168 pts

Location

United States, Austr...

Sponsor

OncoNano Medicine, Inc.

View Trial →

NCT06784167

Recruiting

Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment

OHSU Knight Cancer Institute

View Trial →

NCT03676504 Phase 1, Phase 2

Recruiting

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

University Hospital Heidelberg

View Trial →

NCT06208735 Phase 1

Recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

British Columbia Cancer Agency

View Trial →

NCT06363994 Phase 3

Recruiting

A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL

Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

University College, London

View Trial →

NCT04883437 Phase 2

Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.

Australasian Leukaemia and Lym...

View Trial →

Related Conditions

diffuse large b cell lymphoma (5) follicular lymphoma (4) chronic lymphocytic leukemia (3) high grade b cell lymphoma (2) primary mediastinal large b cell lymphoma (2) small lymphocytic lymphoma (2) marginal zone lymphoma (2) b cell lymphoma (2) non hodgkin lymphoma (1) b cell non hodgkin lymphoma (1) triple negative breast cancer (1) lymphoma non hodgkin (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology